Patents by Inventor Lijuan Wang

Lijuan Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090099847
    Abstract: Detailed herein is a technology which, among other things, reduces errors introduced in recording and transcription data. In one approach to this technology, a method of detecting audio transcription errors is utilized. This method includes selected a focus unit, and selecting a context template corresponding to the focus unit. A hypothesis set is then determined, with reference to the context template and the focus unit. A probability is calculated corresponding to the focus unit, across the hypothesis set.
    Type: Application
    Filed: October 10, 2007
    Publication date: April 16, 2009
    Applicant: Microsoft Corporation
    Inventors: Frank Soong, Lijuan Wang
  • Publication number: 20090083036
    Abstract: Described is a technology by which synthesized speech generated from text is evaluated against a prosody model (trained offline) to determine whether the speech will sound unnatural. If so, the speech is regenerated with modified data. The evaluation and regeneration may be iterative until deemed natural sounding. For example, text is built into a lattice that is then (e.g., Viterbi) searched to find a best path. The sections (e.g., units) of data on the path are evaluated via a prosody model. If the evaluation deems a section to correspond to unnatural prosody, that section is replaced, e.g., by modifying/pruning the lattice and re-performing the search. Replacement may be iterative until all sections pass the evaluation. Unnatural prosody detection may be biased such that during evaluation, unnatural prosody is falsely detected at a higher rate relative to a rate at which unnatural prosody is missed.
    Type: Application
    Filed: September 20, 2007
    Publication date: March 26, 2009
    Applicant: Microsoft Corporation
    Inventors: Yong Zhao, Frank Kao-ping Soong, Min Chu, Lijuan Wang
  • Patent number: 7496512
    Abstract: A method and apparatus are provided for refining segmental boundaries in speech waveforms. Contextual acoustic feature similarities are used as a basis for clustering adjacent phoneme speech units, where each adjacent pair phoneme speech units include a segmental boundary. A refining model is trained for each cluster and used to refine boundaries of contextual phoneme speech units forming the clusters.
    Type: Grant
    Filed: April 13, 2004
    Date of Patent: February 24, 2009
    Assignee: Microsoft Corporation
    Inventors: Yong Zhao, Min Chu, Jian-lai Zhou, Lijuan Wang
  • Publication number: 20070219274
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Application
    Filed: March 29, 2007
    Publication date: September 20, 2007
    Inventors: James Sikorski, Richard Durley, Margaret Grapperhaus, Mark Massa, Emily Reinhard, Yvette Fobian, Michael Tollefson, Lijuan Wang, Brian Hickory, Monica Norton, William Vernier, Deborah Mischke, Michelle Promo, Ashton Hamme, Dale Spangler, Melvin Rueppel
  • Patent number: 7259266
    Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: August 21, 2007
    Assignee: Pharmacia Corporation
    Inventors: Jeffry Carter, David Brown, Li Xing, Karl Aston, John Springer, Francis Koszyk, Steven Kramer, Renee Huff, Yi Yu, Bruce Hamper, Subo Laio, Angela Deprow, Teresa Fletcher, E. Ann Hallinan, James Kiefer, David Limburg, Lijuan Wang, Cindy Ludwig, John McCall, John Talley
  • Patent number: 7253211
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: August 7, 2007
    Assignee: Pfizer Inc.
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Patent number: 7122536
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: October 17, 2006
    Assignee: Pfizer Inc.
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Publication number: 20060229304
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Application
    Filed: March 9, 2006
    Publication date: October 12, 2006
    Inventors: James Sikorski, Richard Durley, Margaret Grapperhaus, Mark Massa, Emily Reinhard, Yvette Fobian, Michael Tollefson, Lijuan Wang, Brian Hickory, Monica Norton, William Vernier, Deborah Mischke, Michele Promo, Ashton Hamme, Dale Spangler, Melvin Rueppel
  • Publication number: 20050228664
    Abstract: A method and apparatus are provided for refining segmental boundaries in speech waveforms. Contextual acoustic feature similarities are used as a basis for clustering adjacent phoneme speech units, where each adjacent pair phoneme speech units include a segmental boundary. A refining model is trained for each cluster and used to refine boundaries of contextual phoneme speech units forming the clusters.
    Type: Application
    Filed: April 13, 2004
    Publication date: October 13, 2005
    Applicant: Microsoft Corporation
    Inventors: Yong Zhao, Min Chu, Jian-lai Zhou, Lijuan Wang
  • Publication number: 20050148627
    Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.
    Type: Application
    Filed: March 16, 2004
    Publication date: July 7, 2005
    Inventors: Jeffery Carter, David Brown, Li Xing, Karl Aston, John Springer, Francis Koszyk, Steven Kramer, Sofya Tsymbalov, Renee Huff, Yi Yu, Bruce Hamper, Subo Laio, Angela Deprow, Theresa Fletcher, E. Hallinan, James Kiefer, David Limburg, Lijuan Wang
  • Publication number: 20050148777
    Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R1, R 2, R3, and R4 are as described in the specification.
    Type: Application
    Filed: March 16, 2004
    Publication date: July 7, 2005
    Inventors: Jeffery Carter, David Brown, Li Xing, Karl Aston, John Springer, Francis Koszyk, Steven Kramer, Renee Huff, Yi Yu, Bruce Hamper, Subo Laio, Angela Deprow, Theresa Fletcher, E. Hallinan, James Kiefer, David Limburg, Lijuan Wang, Cindy Ludwig, John McCall, John Talley
  • Publication number: 20050113451
    Abstract: The present invention relates to 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.
    Type: Application
    Filed: November 1, 2004
    Publication date: May 26, 2005
    Applicant: Pharmacia Corporation
    Inventors: Donald Hansen, Ronald Webber, Barnett Pitzele, James Sikorski, Mark Massa, Timothy Hagen, Margaret Grapperhaus, Lijuan Wang, Arija Bergmanis, Steven Kramer, E. Hallinan
  • Publication number: 20050101641
    Abstract: This invention is directed to aromatic sulfone hydroxamic acids (including hydroxamates) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.
    Type: Application
    Filed: November 17, 2004
    Publication date: May 12, 2005
    Inventors: John Freskos, Yvette Fobian, Thomas Barta, Daniel Becker, Louis Bedell, Terri Boehm, Jeffery Carroll, Gary DeCrescenzo, Susan Hockerman, Darren Kassab, Steve Kolodziej, Joseph McDonald, Deborah Mischke, Monica Norton, Joseph Rico, John Talley, Clara Villamil, Lijuan Wang
  • Publication number: 20050043294
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Application
    Filed: August 27, 2004
    Publication date: February 24, 2005
    Inventors: James Sikorski, Richard Durley, Margaret Grapperhaus, Mark Massa, Emily Reinhard, Yvette Fobian, Michael Tollefson, Lijuan Wang, Brian Hickory, Monica Norton, William Vernier, Deborah Mischke, Michele Promo, Ashton Hamme, Dale Spangler, Melvin Rueppel
  • Publication number: 20050009838
    Abstract: This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.
    Type: Application
    Filed: April 25, 2003
    Publication date: January 13, 2005
    Inventors: Thomas Barta, Daniel Becker, Louis Bedell, Terri Boehm, David Brown, Jeffery Carroll, Yiyuan Chen, Yvette Fobian, John Freskos, Alan Gasiecki, Margaret Grapperhaus, Robert Heintz, Susan Hockerman, Darren Kassab, Ish Khanna, Stephen Kolodziej, Mark Massa, Joseph McDonald, Brent Mischke, Deborah Mischke, Patrick Mullins, Mark Nagy, Monica Norton, Joseph Rico, Michelle Schmidt, Nathan Stehle, John Talley, William Vernier, Clara Villamil, Lijuan Wang, Thomas Wynn
  • Patent number: 6803388
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described. Preferred (R)-Chiral 1-Substitutedamino-(n+1)-Alkanol compounds are substituted (R)-Chiral N,N-bis-phenyl aminoalcohols. A preferred specific (R)-Chiral N,N-bis phenyl aminoclcohol is the compound.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: October 12, 2004
    Assignee: Pfizer, Inc.
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Patent number: 6765023
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted reverse aminoalcohols.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: July 20, 2004
    Assignee: Pfizer, Inc.
    Inventors: James A. Sikorski, Richard C. Durley, Deborah A. Mischke, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Margaret L. Grapperhaus, Brian S. Hickory, Mark A. Massa, Monica B. Norton, William F. Vernier, Barry L. Parnas, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Patent number: 6723752
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1 )-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described. Preferred (R)-Chiral 1-Substitutedamino-(n+1)-Alkanol compounds are substituted (R)-Chiral N-benzyl-N-phenyl aminoalcohols.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: April 20, 2004
    Assignee: Pharmacia Corporation
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Patent number: 6723753
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N-benzyl-N-phenyl aminoalcohols.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: April 20, 2004
    Assignee: Pharmacia Corporation
    Inventors: James A. Sikorski, Richard C. Durley, Deborah A. Mischke, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Margaret L. Grapperhaus, Brian S. Hickory, Mark A. Massa, Monica B. Norton, William F. Vernier, Barry L. Parnas, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Patent number: 6710089
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N-fused-phenyl-N-benzyl aminoalcohols.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: March 23, 2004
    Assignee: Pharmacia Corporation
    Inventors: James A. Sikorski, Richard C. Durley, Deborah A. Mischke, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Margaret L. Grapperhaus, Brian S. Hickory, Mark A. Massa, Monica B. Norton, William F. Vernier, Barry L. Parnas, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel